685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China
685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China is a paper indexed in ScholarIQ from OpenAlex.
How many citations does 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China have?
685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China has 2 citations in the OpenAlex counts ScholarIQ stores.
When was 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China published?
685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China has 2024 year in the ScholarIQ index.
What is the open-access status of 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China?
685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China has bronze oa status in the ScholarIQ index.
What is the DOI of 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China?
The DOI for 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China is on the source record.
What is the OpenAlex record for 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China?
The OpenAlex for 685P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China is on the source record.